non-small cell lung cancer
Conditions
Interventions
adjuvant therapy:targeted therapy and chemotherapy
Sponsors
Department of Thoracic Surgery, the First Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: THE FIRST SECTION:(1) Sublobectomy (wedge resection or segmentectomy)/lobectomy with lymph node sampling or dissection (R0 resection);(2) preoperative CT scan suggests subsolid nodules (CTR>0.25) or solid nodules; (3) Postoperative pathology is adenocarcinoma, staged as IB according to the 8th edition of UICC/AJCC; (4) Genetic testing of tumor tissue suggests deletion of exon 19 and exon L858R point mutation in exon 21, with or without other EGFR mutations; (5) Contains 1 or more of the following risk factors: hypodifferentiated adenocarcinoma, vascular invasion, wedge resection, pleural invasion, unknown lymph node condition (Nx). THE SECOND SECTION: (1) Sublobectomy (wedge resection or segmentectomy)/lobectomy with lymph node sampling or dissection (R0 resection);(2) preoperative CT scan suggests subsolid nodules (CTR>0.25) or solid nodules; (3) Postoperative pathology is non-small cell lung cancer, staged as IB according to the 7th edition of UICC/AJCC; (4) Contains 1 or more of the following risk factors: hypodifferentiated adenocarcinoma, vascular invasion, wedge resection, pleural invasion, unknown lymph node condition (Nx).
Exclusion criteria
Exclusion criteria: THE FIRST SECTION:(1) Preoperative CT suggests pure ground glass nodules or subsolid nodules with a ground glass component greater than 75%; (2) neoadjuvant chemoradiotherapy or targeted therapy before surgery; (3) postoperative pathology is squamous cell carcinoma, carcinoma in situ, micro-invasive carcinoma, metastatic carcinoma and other types of tumors. THE SECOND SECTION: (1) Preoperative CT suggests pure ground glass nodules or subsolid nodules with a ground glass component greater than 75%; (2) neoadjuvant chemoradiotherapy or targeted therapy before surgery; (3) postoperative pathology is carcinoma in situ, micro-invasive carcinoma, metastatic carcinoma and other types of tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Countries
China
Contacts
Public Contactliu yang
the First Medical Center of PLA General Hospital
Outcome results
None listed